4//SEC Filing
ACCENTIA BIOPHARMACEUTICALS INC 4
Accession 0001181431-10-042886
CIK 0001310094operating
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 4:59 PM ET
Size
11.6 KB
Accession
0001181431-10-042886
Insider Transaction Report
Form 4
Pearce Alan M
DirectorChief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2010-02-12+2,500,000→ 2,500,000 totalExercise: $0.44Exp: 2020-02-12→ Common Stock (2,500,000 underlying) - Award
Stock Option (Right to Buy)
2009-02-24+1,000,000→ 1,000,000 totalExercise: $0.18Exp: 2019-02-24→ Common Stock (1,000,000 underlying) - Award
Stock Option (Right to Buy)
2009-02-24+50,000→ 50,000 totalExercise: $0.18Exp: 2019-02-24→ Common Stock (50,000 underlying)
Footnotes (7)
- [F1]Exercise price is 100% of fair market value on date of grant
- [F2]The options shall vest in three equal tranches: (a) one-third on the date of confirmation of the Issuer's Bankruptcy Plan of Reorganization; (b) one-third on the 90th after the date of confirmation of the Issuer's Bankruptcy Plan of Reorganization; and (c) one-third on the 180th after the date of confirmation of the Issuer's Bankruptcy Plan of Reorganization. Shares underlying the options are restricted as to resale until the 12- month anniversary of the effective date of the Issuer's Bankruptcy Plan of Reorganization.
- [F3]Options terminate 10 years from grant date, or 90 days after the non-employee director ceases to be a director for any reason, other than death, disability or retirement.
- [F4]Stock options acquired pursuant to the Issuer's plan of compensation for Directors.
- [F5]Stock options acquired pursuant to the Issuer's plan of compensation for Employees.
- [F6]The option shall become 100% vested upon effective date of the Issuer's Bankruptcy Plan of Reorganization and the first to occur of a) six (6) months following the closing of a capital raise by the Issuer's with gross proceeds of a minimum of $5.0 million; or b) two (2) years from the effective date of the Issuer's Bankruptcy Plan. Shares underlying the options are restricted as to resale until the 12- month anniversary of the effective date of the Issuer's Bankruptcy Plan of Reorganization.
- [F7]Options terminate 10 years from grant date, or 90 days after the employee ceases to be employed by the Issuer for any reason, other than death, disability or retirement.
Documents
Issuer
ACCENTIA BIOPHARMACEUTICALS INC
CIK 0001310094
Entity typeoperating
IncorporatedFL
Related Parties
1- filerCIK 0001310094
Filing Metadata
- Form type
- 4
- Filed
- Aug 19, 8:00 PM ET
- Accepted
- Aug 20, 4:59 PM ET
- Size
- 11.6 KB